Oxford diagnostics company raises £12.3 million for development of tests
Sense Biodetection, a diagnostics company which operates from both Cambridge and Oxford, has raised £12.3 million to develop a new range of tests, with the main focus being to target infectious diseases like flu.
The money raised will be added to a £1.8 million grant received from Innovate UK and an already secured £10.5 million Series A investment from a consortium that includes, Cambridge Innovation Capital (CIC), Earlybird, Founder Johnathan Milner and existing investor, Mercia.
The company continues to focus it’s work on the development of instrument-free molecular diagnostics, which represents the ultimate flexible test format, aimed at transforming the industry by delivering, for the first time, true point-of-care molecular testing. These new products will allow rapid tests for viral and bacterial pathogens, such as those causing respiratory infections or sexually transmitted diseases. Developments will allow these tests to be performed within minutes in a doctors’ office, pharmacy or community facility, ensuring more timely treatment and management of infections.
“With the support of an exceptional new investment syndicate and continued support from Mercia, Sense is positioned to become first-in-class and best-in-class in the exciting new field of instrument-free molecular diagnostics and to realise its vision to transform healthcare through decentralisation.”
Harry Lamble, CEO at Sense